Managing genomic and proteomic knowledge

Drug Discovery Today: Technologies

Volumn 2, Issue 3, 2005, Pages 197-204

  Lutz, Michael W ^a   Warren, Patrick V ^a   Gill, Rob W ^a   Searls, David B ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL NUCLEUS RECEPTOR; MEMBRANE RECEPTOR; MESSENGER RNA; PHOSPHOTRANSFERASE;

ALGORITHM; BIOINFORMATICS; BIOTECHNOLOGY; CLINICAL PRACTICE; CLINICAL RESEARCH; COMPUTER PROGRAM; DATA ANALYSIS; DNA MICROARRAY; DRUG INFORMATION; DRUG RESEARCH; DRUG TARGETING; GENE EXPRESSION; GENETIC DATABASE; GENETIC SUSCEPTIBILITY; GENOMICS; GENOTYPE; HUMAN; INFORMATION PROCESSING; INTERNET; KNOCKOUT GENE; NONHUMAN; PHENOTYPE; PHYLOGENY; PROTEIN TARGETING; PROTEOMICS; REVIEW; RNA INTERFERENCE; SIGNAL NOISE RATIO; STANDARDIZATION; STATISTICAL MODEL;

EID: 27244454362     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2005.08.001     Document Type: Review

References (46)

1. J.A. Bilello The agony and ecstasy of "OMIC" technologies in drug development Curr. Mol. Med. 5 2005 39-52
2. A. Kahraman et al. PhenomicDB: A multi-species genotype/phenotype database for comparative phenomics Bioinformatics 21 2005 418-420
3. Wu, Z.J. and Irizarry, R.A. (2005) A Statistical Framework for the Analysis of Microarray Probe-Level Data. Johns Hopkins University, Dept. of Biostatistics Working Papers.
4. D.B. Searls Data integration: Challenges for drug discovery Nat. Rev. Drug Discov. 4 2005 45-58
5. P. Shannon et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks Genome Res. 13 2003 2498-2504
6. T. Hastie The Elements of Statistical Learning 2001 Springer
7. D.B. Searls Pharmacophylogenomics: Genes, evolution and drug targets Nat. Rev. Drug Discov. 2 2003 613-623
8. J.R. Brown et al. Evolutionary relationships of Aurora kinases: implications for model organism studies and the development of anti-cancer drugs BMC Evol. Biol. 4 2004 39
9. L. Hood et al. Systems biology and new technologies enable predictive and preventive medicine Science 306 2004 640-643
10. M. Steffen et al. Automated modelling of signal transduction networks BMC Bioinformatics 3 2002 34
11. E. Yeger-Lotem et al. Network motifs in integrated cellular networks of transcription-regulation and protein-protein interaction Proc. Natl. Acad. Sci. U.S.A. 101 2004 5934-5939
12. D. Schober et al. GandrKB - ontological microarray annotation and visualization Bioinformatics 21 2005 2785-2786
13. A.G. Fraser and E.M. Marcotte A probabilistic view of gene function Nat. Genet. 36 2004 559-564
14. D. di Bernardo et al. Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks Nat. Biotechnol. 23 2005 377-383
15. M. Bredel and E. Jacoby Chemogenomics: An emerging strategy for rapid target and drug discovery Nat. Rev. Genet. 5 2004 262-275
16. C. Kung et al. Chemical genomic profiling to identify intracellular targets of a multiplex kinase inhibitor Proc. Natl. Acad. Sci. U.S.A. 102 2005 3587-3592
17. A.D. Roses Pharmacogenetics and drug development: The path to safer and more effective drugs Nat. Rev. Genet. 5 2004 645-656
18. A.D. Roses Genome-based pharmacogenetics and the pharmaceutical industry Nat. Rev. Drug Discov. 1 2002 541-549
19. A.D. Roses et al. Disease-specific target selection: A critical first step down the right road Drug Discov. Today 10 2005 177-189
20. M. Morley et al. Genetic analysis of genome-wide variation in human gene expression Nature 430 2004 743-747
21. R. Frank and R. Hargreaves Clinical biomarkers in drug discovery and development Nat. Rev. Drug Discov. 2 2003 566-580
22. J. Quackenbush Microarray data normalization and transformation Nat. Genet. Suppl. 32 2002 496-501
23. B.C. Bond et al. The quantification of gene expression in an animal model of brain ischaemia using TaqMan™ real-time RT-PCR Mol. Brain Res. 106 2002 101-116
24. D.P. Kreil et al. DNA microarray normalization methods can remove bias from differential protein expression analysis of 2D gel electrophoresis results Bioinformatics 20 2004 2026-2034
25. A.D. Chisholm H.R. Horvitz Patterning of the Caenorhabditis elegans head region by the Pax-6 family member vab-3 Nature 377 1995 52-55
26. C.A. Heid et al. Genome Res. 6 1996 986-994
27. R. Higuchi et al. Simultaneous amplification and detection of specific DNA sequences Biotechnology 10 1992 413-417
28. R. Higuchi et al. Kinetic PCR: Real time monitoring of DNA amplification reactions Biotechnology 11 1993 1026-1030
29. M. Schena et al. Quantitative monitoring of gene expression patterns with a complimentary DNA microarray Science 270 1995 467-470
30. S.P. Fodor et al. Light-directed, spatially addressable parallel chemical synthesis Science 251 1991 767-773
31. S.P. Fodor et al. Multiplexed biochemical assays with biological chips Nature 364 1993 555-556
32. D. Rajagopalan A comparison of statistical methods for analysis of high density oligonucleotide array data Bioinformatics 19 2003 1469-1476
33. F. Colland and L. Daviet Integrating a functional proteomic approach into the target discovery process Biochimie 86 2004 625-632
34. P. Legrain and L. Selig Genome-wide protein interaction maps using two-hybrid systems FEBS Lett. 480 2000 32-36
35. S. Cho et al. Protein-protein interaction networks: From interactions to networks J. Biochem. Mol. Biol. 37 2004 45-52
36. P.G. Righetti et al. Critical survey of quantitative proteomics in two-dimensional electrophoretic approaches J. Chromatogr. A 1051 2004 3-17
37. Y. Shi et al. The role of liquid chromatography in proteomics J. Chromatogr. A 1053 2004 27-36
38. J.M. Jacobs et al. Ultra-sensitive, high-throughput and quantitative proteomics measurements Int. J. Mass Spectrom. 240 2005 195-212
39. X. Chen et al. Chemical modification of gene silencing oligonucleotides for drug discovery and development Drug Discov. Today 10 2005 195-212
40. G.J. Hannon and J.J. Rossi Unlocking the potential of the human genome with RNA interference Nature 431 2004 371-378
41. S. Harris and S.M. Foord Transgenic gene knock-outs: Functional genomics and therapeutic target selection Pharmacogenomics 1 2000 433-443
42. J. Tornell and M. Snaith Transgenic systems in drug discovery: From target identification to humanized mice Drug Discov. Today 7 2002 461-470
43. J.L. Griffin and M.E. Bollard Metabonomics: Its potential as a tool in toxicology for safety assessment and data integration Curr. Drug Metab. 5 2004 389-398
44. S.M. Watkins et al. Lipid metabolome-wide effects of the PPARγ agonist rosiglitazaone J. Lipid Res. 43 2002 1809-1817
45. J.K. Nicholson et al. Metabonomics: A platform for studying drug toxicity and gene function Nat. Rev. Drug Discov. 1 2002 153-161
46. S.M. Watkins Lipomic profiling in drug discovery, development and clinical trial evaluation Curr. Opin. Drug Discov. Dev. 7 2004 112-117